This study retrospectively investigated bone remineralization in patients with newly diagnosed multiple myeloma under a quadruple induction therapy of carfilzomib, lenalidomide, dexamethasone and the anti-SLAMF7 monoclonal antibody elotuzumab. The gene discussed is SLAMF7; the disease is plasma cell myeloma.